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An atypical presentation of a rare disease
Elizabeth Schoenberg, BA, Kathleen P. McGuinn, MD, Deirdre Connolly, MD, and Sherry Yang, MD
Philadelphia, Pennsylvania
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HISTORY
A 76-year-old white woman presented for evaluation of asymptomatic skin lesions on her right shin, right
buttock, and left arm. All lesions initially underwent slow growth and plateaued and then remained stable in
size. A complete review of systems revealed normal results. She had 3 well-demarcated erythematous round
plaques ranging from 1.5 to 3 cm, all with a central depression, yellow hue, and prominent telangiectasias (Figs 1
and 2). An excisional biopsy was performed. Histologically, there were palisading granulomas within the
papillary and reticular dermis, predominantly composed of a histiocytic cell populationwith multiple large giant
cells (S100-; Fig 3).
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Question 1: What is the diagnosis?
A. Xanthelasma
B. Necrobiotic xanthogranuloma (NXG)
C. Necrobiosis lipoidica (NL)
D. Sarcoidosis
E. Xanthoma disseminatum (XD)
Answers:
A. Xanthelasma e Incorrect. Xanthelasmas are
noninflammatory soft yellow-orange cholesterol-
containing lesions usually present on the eyelids.
Histologically, xanthelasmas contain foam cells in
the papillary dermis.
B. NXG e Correct. NXG usually presents with
multiple asymptomatic lesions. Lesions of NXG
typically first appear on the trunk or extremities in
60% to 70% of patients, then eventually progress to
characteristic periorbital involvement in 80% to 85%
of cases. Patients commonly present with an indu-
rated papule, nodule, or plaque with a yellowish
hue sometimes with telangiectasias, atrophy, or
ulceration. Histologically, palisading granulomas
are usually seen in the dermis. The granulomas
often contain lipidized histiocytes (foam cells), giant
cells, plasma cells, and cholesterol clefts.
C. NL e Incorrect. NL presents as an evolving
lesion beginning with red to brown papules or
plaques progressing into an atrophic, telangiectatic,
yellow lesion. NL and NXG share similar features
microscopically including hyalinized collagen
within the necrobiotic area. However, NXG often
displays Touton cells and atypical giant cells and
may be distinguished histologically by cholesterol
clefts within the granuloma. NL displays lipids
altering with collagen bundles causing a layering
of hyalinized collagen described as a wedding cake
appearance.1
D. Sarcoidosis e Incorrect. Cutaneous sarcoid
often presents with bilaterally symmetrical red-
brownecolored lesions. The hallmark on pathology
is the presence of naked tubercles meaning the
presence of epithelioid cell granulomas without
prominent lymphocytes, plasma cells, or caseation.
E. XD e Incorrect. XD manifests with an eruption
of hundreds of yellow, red, or brown papules that
tend to cluster. The lesions are often symmetrical
and affect the face, trunk, and intertriginous areas of
the extremities.
Question 2:Which of the following is associated
with NXG?
A. Diabetes mellitus
B. Lung disease
C. Multiple myeloma or monoclonal gammopathy
of undetermined significance (MGUS)
D. Diabetes insipidus (DI)
E. Hyperlipidemia
Answers:
A. Diabetes mellitus e Incorrect. NL has been
classically associated with diabetes mellitus. The
reported prevalence of diabetes mellitus in patients
with NL ranges from 11% to 65%.2
B. Lung disease e Incorrect. Ninety percent of
patients with sarcoidosis suffer from lung involve-
ment causing granulomatous inflammation in any
part of the lung and may ultimately cause the
patient to suffer from bronchiectasis.
C. Multiple myeloma or MGUS e Correct. The
etiology of the NXG is unclear; however, up to 80%
of patients can have associated monoclonal gammo-
pathies, most commonly IgG-k; this can precede or
follow the onset of cutaneous lesions by many years.3
In this patient, serum protein electrophoresis was
significant for an elevated serum monoclonal protein
at 0.34 g/dL (normal range, #0). Immunofixation
identified a monoclonal protein band composed of
IgG-l. MGUS was subsequently diagnosed.
D. DI e Incorrect. DI is associated with XD in
approximately 40% of cases.4 However, DI is usu-
ally mild in these patients and is amenable to
treatment with vasopressin.4
E. Hyperlipidemia e Incorrect. Hyperlipidemia
has been associated with xanthelasmas in about
50% of patients.5
Question 3: Which of the following would NOT
be an appropriate treatment option for this
patient?
A. Observation
B. Alkylating chemotherapeutic agents
C. Corticosteroids
D. Intravenous immunoglobulin
E. Antimetabolites (methotrexate or azathioprine)
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Answers:
A. Observation e Incorrect. Observation is an
appropriate option for patients with NXG. Our
patient was referred to hematology-oncology for
further workup. The patient elected to be closely
monitored in lieu of pursuing treatment, as her
lesions remained stable in size, and her MGUS had
not progressed.
B. Alkylating chemotherapeutic agents e Incor-
rect. Alkylating chemotherapeutic agents are the
most common systemic treatment for NXG, espe-
cially Chlorambucil, which is used in low doses for
patients with associated paraproteinemia.6
C. Corticosteroids e Incorrect. Topical steroids
may be used for small NXG areas, and intralesional
injections have been used with mixed results. Sys-
temic corticosteroids as monotherapy display a high
relapse rate after discontinuation. Systemic cortico-
steroids may be used in combination with alkylating
agents.6
D. Intravenous Immunoglobulin e Incorrect.
Intravenous immunoglobulin has shown rapid
remission in patients with NXG and an underlying
hematologic disorder.6 If other treatment modalities
fail, intravenous immunoglobulin may be
considered.6
E. Antimetabolites (methotrexate or azathio-
prine) e Correct. The use of antimetabolites has
not proven to be an effective treatment option.
Antimetabolites have not been studied since the
1980s and at the time had only produced a partial
remission of symptoms. Ultimately, a patient who
received both methotrexate and azathioprine actu-
ally experienced additional lesions.6 Antimetabo-
lites have not been included in recent treatment
regimens.
Abbreviations used:
DI: diabetes insipidus
MGUS: monoclonal gammopathy of undetermined
significance
NL: necrobiosis lipoidica
NXG: necrobiotic xanthogranuloma
XD: xanthoma disseminatum
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